Amagma was founded in 2019 by serial entrepreneurs Tillman Gerngross, Ph.D. and Leonard Zon, M.D., to develop novel antibody therapies targeting diseases resulting from the dysfunction of essential proteases and other enzymes. These targets have long been of interest to the biopharmaceutical industry, but, despite this, there remain significant unmet medical needs across the many inflammatory conditions caused by protease dysfunction.
